Anticancer activity of dihydropyrazolo[1,5-c]quinazolines against rat C6 glioma cells via inhibition of topoisomerase II

Arch Pharm (Weinheim). 2018 Jun;351(6):e1800023. doi: 10.1002/ardp.201800023. Epub 2018 May 8.

Abstract

The design and synthesis of dihydropyrazolo[1,5-c]quinazolines (1a-h) as human topoisomerase II (TopoII) catalytic inhibitors are reported. The compounds were investigated for their antiproliferative activity against the C6 rat glial cell line. Two compounds, 1b and 1h, were found to be potent cytotoxic agents against glioma cells and exerted selective TopoII inhibitory activity. Furthermore, the compounds induced alterations in reactive oxygen species levels as measured by DCFDA assay and were found to induce cell cycle arrest at the G1 phase at lower concentrations and profound apoptosis at higher concentrations. The interaction of selected investigational molecules with TopoII was further corroborated by molecular modeling.

Keywords: cancer; cell cycle; dihydropyrazolo[1,5-c]quinazoline; rat C6 glioma cells; topoisomerases.

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • DNA Topoisomerases, Type II / drug effects
  • DNA Topoisomerases, Type II / metabolism
  • Dose-Response Relationship, Drug
  • G1 Phase Cell Cycle Checkpoints / drug effects
  • Glioma / drug therapy*
  • Glioma / enzymology
  • Humans
  • Models, Molecular
  • Quinazolines / chemical synthesis
  • Quinazolines / chemistry
  • Quinazolines / pharmacology*
  • Rats
  • Reactive Oxygen Species / metabolism
  • Topoisomerase II Inhibitors / chemical synthesis
  • Topoisomerase II Inhibitors / chemistry
  • Topoisomerase II Inhibitors / pharmacology*

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Reactive Oxygen Species
  • Topoisomerase II Inhibitors
  • DNA Topoisomerases, Type II